Incendia Therapeutics President & CEO Wendye Robbins is featured in GBHNews' new Women in Biotech series. Hear her perspective on leadership and empowering women in biotech. https://lnkd.in/eDisnDNF
Incendia Therapeutics
Biotechnology Research
Cambridge, Massachusetts 4,851 followers
About us
Incendia Therapeutics is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment. Many cancers create immune exclusion barriers that prevent the immune system from attacking tumors. Our approach to overcoming these barriers is to modulate the interplay among cancer cells, stromal cells, and immune cells. Our lead program, PRTH-101, is a first-in-class humanized monoclonal antibody that blocks the interaction of Discoidin Domain Receptor 1 (DDR1) with collagen, thereby “punching holes” in the extracellular matrix barrier created by the tumor. With the extracellular matrix barrier breached, immune cells are able to infiltrate and attack the tumor. PRTH-101 is poised to enter Phase 1 clinical trials. PRTH-101 is followed by a pipeline of preclinical projects targeting orthogonal components of the tumor microenvironment that promote immune exclusion. Incendia combines its drug discovery and development efforts with a precision oncology approach to get the right medicines to the right patients. We use proprietary AI technology to digitally deconstruct the TME and develop unique insights to enable biomarker-driven patient selection strategies designed to guide clinical applications.
- Website
-
http://www.incendiatx.com
External link for Incendia Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
Locations
-
Primary
Get directions
1 Canal Park
Suite 200
Cambridge, Massachusetts 02141, US
Employees at Incendia Therapeutics
-
Nancy Shuman Carbone
Senior Executive Assistant specializing in Leadership Communication and Operations at Incendia Therapeutics
-
Michael Baran
Partner - Pfizer Ventures
-
Wendye Robbins
A physician / CEO with a deep track record in translational science and drug development.
-
Chris O'Donnell
Partner, Pfizer Ventures & Vice President, Partnering Innovations
Updates
-
Incendia Therapeutics is excited to announce the appointment of Dr. Louis Lange to our Board of Directors. Dr. Lange, a General Partner with Asset Management Ventures, Inc., is a highly successful biotechnology investor and serial entrepreneur with deep experience building companies that have generated scientific breakthroughs and significant value for patients and investors. For more details, click on the news release link at https://lnkd.in/eNFmEKrA. #tumormicroenvironment #cancer #biotech #innovation #Boardofdirectors
-
-
Incendia Therapeutics reposted this
Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer https://lnkd.in/gnr2tAsD Your go-to for local business news. Follow citybiz Incendia Therapeutics #biotechnology #chieffinanicalofficer
Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer
https://www.citybiz.co
-
Please join Incendia Therapeutics in welcoming Brad Smith as our Chief Financial Officer (https://lnkd.in/ePr9wfXb). Brad is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies, including experience in private and public equity financings with more than $1 billion raised. For more details, click on the news release link or visit the “News” page of Incendia's website (www.incendiatx.com). #tumormicroenvironment #cancer #biotech #innovation #CFO Brad Smith Wendye Robbins
-
-
Celebrating Thanksgiving with a potluck lunch at Incendia Therapeutics! Delicious dishes were prepared and enjoyed by everyone. Support, collaboration and team spirit have made this event truly special. Here is to continued success, health and happiness.
-
-
Incendia Therapeutics presented three posters at the 39th annual meeting of the Society for Immunotherapy of Cancer (SITC) in Houston. Congratulations to our research partners and team members who led this research illustrating the important role of the tumor microenvironment in solid cancers. To download the posters, visit the “Presentations and Publications” page of Incendia’s website (www.incendiatx.com) or click on the links provided next to the poster titles below. Exclusion of CD8 T Cells from Tumor Epithelium is Associated with Worse Immune Checkpoint Blockade (ICB) Therapy Response and Survival in Non-Small Cell Lung Cancer (NSCLC) https://lnkd.in/etekc6Nn Spatial transcriptomics analysis reveals association between DDR1-collagen interactions and immune exclusion in human cancers https://lnkd.in/ef-eud99 Stromal collagen features from H&E-stained whole slide images are associated with lymphocyte infiltration and survival following checkpoint inhibition in patients with non-small cell lung cancer https://lnkd.in/eWCuabYW #cancer #immunotherapy #biotech #innovation #SITC2024
-
-
Incendia Therapeutics is proud to announce the presentation of new clinical data from a Phase 1 study of PRTH-101 at the International Thymic Malignancy Interest Group Annual Meeting 2024 in Yokohama, Japan. To download a PDF of the poster, scan the QR code within this posting or visit the “Presentations and Publications” page of Incendia’s website. https://lnkd.in/eU_hDuWb Thank you to the investigators, patients and their families for their participation in this trial. Susan Macdonald Thomas Schürpf #cancer #thymiccancer #biotech #innovation #ITMIG
-
-
Incendia Therapeutics reposted this
Terrific discussion on lessons learned and surprises manged in #biotech company formation w/ Atavistik Bio Entrada Therapeutics Mural Oncology Incendia Therapeutics & Progentos
-
-
Incendia Therapeutics CEO Wendye Robbins will join esteemed industry leaders in a panel discussion addressing “Company Formation: Building a Biotech" at Boston CEO on Monday, October 28th. Learn more at Longwood Healthcare Leaders. #longwoodhealthcareleaders #BostonCEO #biotech #innovation
Hear the surprises, hurdles, and strategies for optimization from #biotech founders and CEOs. See the full lineup and join us for #BostonCEO October 28-29 https://lnkd.in/eehfZ2xB
-
-
Fanning the flames of innovation keeps the engines running in the life science industry. Incendia CEO Wendye Robbins helped stoke her colleagues’ passion by participating in the Alumni Panel during today’s JLABS Global CEO Summit at the New York Stock Exchange. #innovation #biotech #research
-